title: Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia.
authors.forename: Byung Gil
authors.initials: BG
authors.lastname: Moon
authors.forename: Yoon Jeon
authors.initials: YJ
authors.lastname: Kim
authors.forename: Young Hee
authors.initials: YH
authors.lastname: Yoon
authors.forename: Joo Yong
authors.initials: JY
authors.lastname: Lee
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002199:Capillary Permeability; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000473:pathology; D058456:Retinal Telangiectasis / Q000188:drug therapy* / Q000503:physiopathology; D019233:Retreatment; D012189:Retrospective Studies; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab